Pleuropulmonary blastoma: the decisions you may face

Cancer page →Second-opinion finder →

2 treatment settings, 1 with more than one named option. Each section lays out the options the standard of care names, what each is for, the trials behind them with their recorded results, the side effects and cautions on record, and questions to ask. Built from the cancer page's standard-of-care rows; nothing here is advice for your case.

Other settings

Type I and Ir

One path named

Complete resection of the cyst; chemotherapy debated; DICER1 testing and surveillance.

The path, in plain words

Germline (hereditary) testingStandard of care

A test of the DNA you were born with, to find inherited risk genes such as BRCA or Lynch syndrome.

Actionable for patient and relatives
Cheap

Also referenced:Childhood lung and airway tumours (pleuropulmonary blastoma, tracheobronchial tumours)

The evidence behind it

No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.

The main trade-offs on record

Germline (hereditary) testing

VUS burden
Uptake and counselling capacity

Questions to ask about this decision

Is Germline (hereditary) testing the only reasonable path for me, or is there a trial, a different sequence or a wait-and-see option?
Why: A single standard does not mean a single choice; timing and trials are decisions too.
What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?
Why: The aim shapes how much side effect and disruption is worth accepting.
What happens if I delay, or decline this step for now? Is the decision reversible?
Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
For my situation (type i and ir), which of the standard options do you recommend and why?
Why: Guideline options include: Complete resection of the cyst; chemotherapy debated; DICER1 testing and surveillance.

Add these to your appointment list, or take the full question set for this cancer.

Other settings

Type II and III

3 optionsCompare side by side →

Resection and multi-agent chemotherapy (ifosfamide, vincristine, actinomycin, doxorubicin), radiotherapy for residual disease.

The options, in plain words

IfosfamideApprovedCytotoxic chemotherapy (alkylating agent)

Ifosfamide is an alkylating chemotherapy partnered with doxorubicin in sarcoma and with etoposide in Ewing sarcoma, given with a bladder-protecting drug.

VincristineApprovedVinca alkaloid (microtubule inhibitor)

A plant-derived chemotherapy from the Madagascar periwinkle that has been in almost every childhood leukaemia and lymphoma regimen since the 1960s.

DoxorubicinApprovedCytotoxic chemotherapy (anthracycline)

The red chemotherapy drug from a soil bacterium that is still the backbone of treatment for sarcoma, lymphoma and breast cancer, limited by cumulative heart damage.

Also referenced:Childhood lung and airway tumours (pleuropulmonary blastoma, tracheobronchial tumours)

The evidence behind it

No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.

The main trade-offs on record

Ifosfamide all recorded rates →

Side effect	Any grade	Grade 3+
Febrile neutropenia (with doxorubicin) · EORTC 62012, intensified doxorubicin plus ifosfamide arm (103 of 224); 13% with doxorubicin alone	-	46%
Central nervous system toxicity, including encephalopathy · Ifosfamide monotherapy trials pooled in the label (154 of 1001)	15.4%	-
Visible blood in the urine (macroscopic haematuria) · With mesna, ifosfamide monotherapy trials pooled in the label (5 of 97); 11.1% without mesna	5.2%	-

Rates from the label or pivotal trial as recorded on the product page; each grade 3+ figure links to its source.

Vincristine all recorded rates →

Fatal if given intrathecally: label all syringes.

Doxorubicin all recorded rates →

Side effect	Any grade	Grade 3+
Neutropenia · Doxorubicin 75 mg/m2 with placebo, ANNOUNCE control arm (49.0%)	-	49%
Alopecia · Doxorubicin with cyclophosphamide (AC), adjuvant breast cancer, N=1492; the label gives no sarcoma figure	92%	-

Cumulative dose: risk rises steeply above 400-550 mg/m² (see the anthracycline calculator).
Reduce by 50% for bilirubin 20-50 µmol/L and 75% for 50-85 µmol/L.

Rates from the label or pivotal trial as recorded on the product page; each grade 3+ figure links to its source.

Questions to ask about this decision

Between Ifosfamide, Vincristine and Doxorubicin, which do you recommend for me, and what about my case would make you choose differently?
Why: Guidelines list several reasonable options; the choice turns on details of your tumour, your health and your priorities.
What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?
Why: The aim shapes how much side effect and disruption is worth accepting.
Which side effects of Ifosfamide or Doxorubicin are most likely for me, which are reversible, and which would make us stop?
Why: The recorded rates below come from labels and trials; your own risk depends on dose, other medicines and your health.
What happens if I delay, or decline this step for now? Is the decision reversible?
Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
For my situation (type ii and iii), which of the standard options do you recommend and why?
Why: Guideline options include: Resection and multi-agent chemotherapy (ifosfamide, vincristine, actinomycin, doxorubicin), radiotherapy for residual disease.
Am I a candidate for Ifosfamide, Vincristine, Doxorubicin, and what side effects should I expect?
Why: Knowing the expected toxicities helps you plan work, family, and supportive care.

Add these to your appointment list, or take the full question set for this cancer.

How to read this page. Options and results come from OnCo records with their sources; the settings are the standard-of-care rows on the cancer page, and the lines of therapy are on the sequencing grid. Where a setting names one path, the choice is usually about timing, trials and where to be treated: see expert centres. OnCo is orientation, not medical advice.

Living with cancer·Standard of care

Pleuropulmonary blastoma: the decisions you may face

Cancer page →Second-opinion finder →

Other settings

Type I and Ir

One path named

Complete resection of the cyst; chemotherapy debated; DICER1 testing and surveillance.

The path, in plain words

Germline (hereditary) testingStandard of care

A test of the DNA you were born with, to find inherited risk genes such as BRCA or Lynch syndrome.

Actionable for patient and relatives
Cheap

Also referenced:Childhood lung and airway tumours (pleuropulmonary blastoma, tracheobronchial tumours)

The evidence behind it

No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.

The main trade-offs on record

Germline (hereditary) testing

VUS burden
Uptake and counselling capacity

Questions to ask about this decision

Is Germline (hereditary) testing the only reasonable path for me, or is there a trial, a different sequence or a wait-and-see option?
Why: A single standard does not mean a single choice; timing and trials are decisions too.
What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?
Why: The aim shapes how much side effect and disruption is worth accepting.
What happens if I delay, or decline this step for now? Is the decision reversible?
Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
For my situation (type i and ir), which of the standard options do you recommend and why?
Why: Guideline options include: Complete resection of the cyst; chemotherapy debated; DICER1 testing and surveillance.

Add these to your appointment list, or take the full question set for this cancer.

Other settings

Type II and III

3 optionsCompare side by side →

Resection and multi-agent chemotherapy (ifosfamide, vincristine, actinomycin, doxorubicin), radiotherapy for residual disease.

The options, in plain words

IfosfamideApprovedCytotoxic chemotherapy (alkylating agent)

Ifosfamide is an alkylating chemotherapy partnered with doxorubicin in sarcoma and with etoposide in Ewing sarcoma, given with a bladder-protecting drug.

VincristineApprovedVinca alkaloid (microtubule inhibitor)

A plant-derived chemotherapy from the Madagascar periwinkle that has been in almost every childhood leukaemia and lymphoma regimen since the 1960s.

DoxorubicinApprovedCytotoxic chemotherapy (anthracycline)

The red chemotherapy drug from a soil bacterium that is still the backbone of treatment for sarcoma, lymphoma and breast cancer, limited by cumulative heart damage.

Also referenced:Childhood lung and airway tumours (pleuropulmonary blastoma, tracheobronchial tumours)

The evidence behind it

No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.

The main trade-offs on record

Ifosfamide all recorded rates →

Side effect	Any grade	Grade 3+
Febrile neutropenia (with doxorubicin) · EORTC 62012, intensified doxorubicin plus ifosfamide arm (103 of 224); 13% with doxorubicin alone	-	46%
Central nervous system toxicity, including encephalopathy · Ifosfamide monotherapy trials pooled in the label (154 of 1001)	15.4%	-
Visible blood in the urine (macroscopic haematuria) · With mesna, ifosfamide monotherapy trials pooled in the label (5 of 97); 11.1% without mesna	5.2%	-

Rates from the label or pivotal trial as recorded on the product page; each grade 3+ figure links to its source.

Vincristine all recorded rates →

Fatal if given intrathecally: label all syringes.

Doxorubicin all recorded rates →

Side effect	Any grade	Grade 3+
Neutropenia · Doxorubicin 75 mg/m2 with placebo, ANNOUNCE control arm (49.0%)	-	49%
Alopecia · Doxorubicin with cyclophosphamide (AC), adjuvant breast cancer, N=1492; the label gives no sarcoma figure	92%	-

Cumulative dose: risk rises steeply above 400-550 mg/m² (see the anthracycline calculator).
Reduce by 50% for bilirubin 20-50 µmol/L and 75% for 50-85 µmol/L.

Rates from the label or pivotal trial as recorded on the product page; each grade 3+ figure links to its source.

Questions to ask about this decision

Between Ifosfamide, Vincristine and Doxorubicin, which do you recommend for me, and what about my case would make you choose differently?
Why: Guidelines list several reasonable options; the choice turns on details of your tumour, your health and your priorities.
What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?
Why: The aim shapes how much side effect and disruption is worth accepting.
Which side effects of Ifosfamide or Doxorubicin are most likely for me, which are reversible, and which would make us stop?
Why: The recorded rates below come from labels and trials; your own risk depends on dose, other medicines and your health.
What happens if I delay, or decline this step for now? Is the decision reversible?
Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
For my situation (type ii and iii), which of the standard options do you recommend and why?
Why: Guideline options include: Resection and multi-agent chemotherapy (ifosfamide, vincristine, actinomycin, doxorubicin), radiotherapy for residual disease.
Am I a candidate for Ifosfamide, Vincristine, Doxorubicin, and what side effects should I expect?
Why: Knowing the expected toxicities helps you plan work, family, and supportive care.

Add these to your appointment list, or take the full question set for this cancer.